Remsima 120 mg SC Infliximab Biosimilar Pre-filled Pen

Remsima 120 mg SC (Infliximab Biosimilar) Pre-filled Pen — Complete Guide

Key Facts Table

Short Description

Remsima SC is an EMA-approved subcutaneous infliximab. It neutralizes TNF-alpha, a central inflammatory signal in autoimmune disease, to reduce symptoms and help protect joints and the gut. As the first subcutaneous infliximab, it lets suitable patients continue infliximab therapy at home instead of returning for infusions.

Table of Contents

• Introduction
• What Is Remsima SC?
• How Does It Work?
• Main Benefits
• Real Use Cases
• Who Is It Best For?
• Who Should Avoid It?
• How to Use Correctly
• Best Time to Use
• Common Questions Users Ask
• Expected Results Timeline
• Common Mistakes
• Myths vs Facts
• Drug Interactions
• Contraindications
• Required Tests
• What to Eat With It
• Effect on Other Medications
• When To See a Doctor
• NSL Expert Tip
• Conversational FAQ
• Conclusion

Introduction

Infliximab has been a mainstay biologic for inflammatory arthritis and inflammatory bowel disease for years, but it traditionally required hospital infusions. Remsima SC changes that: it is the first infliximab delivered as a fixed-dose subcutaneous injection, giving stable patients the freedom to self-inject at home every two weeks. For people who respond well to infliximab but find infusion visits burdensome, this format preserves proven efficacy while improving day-to-day convenience.

What Is Remsima SC?

Remsima is a biosimilar of infliximab (reference: Remicade), a monoclonal antibody against TNF-alpha. The subcutaneous 120 mg pen or syringe delivers a fixed dose regardless of body weight in most patients. It is approved across rheumatology, gastroenterology, and dermatology for the same conditions as intravenous infliximab, and treatment is usually started with loading doses before moving to subcutaneous maintenance.

How Does It Work?

Tumor necrosis factor alpha (TNF-alpha) is an inflammatory messenger that is overactive in autoimmune conditions, driving joint destruction, bowel inflammation, and skin plaques. Infliximab binds TNF-alpha and blocks it from activating its receptors. With this signal switched off, inflammation subsides, symptoms ease, and long-term structural damage in joints and gut is reduced.

Main Benefits

• First subcutaneous infliximab — at-home dosing instead of hospital infusions.
• Fixed 120 mg dose every two weeks simplifies the schedule.
• Covers a broad range of TNF-driven autoimmune diseases.
• Helps reduce symptoms and slow joint and bowel damage.
• Biosimilar pricing supports sustainable long-term treatment.
• More stable drug levels than intermittent infusions in some patients.

Real Use Cases

• A rheumatoid arthritis patient stable on IV infliximab who wants to switch to at-home injections.
• A Crohn’s disease patient needing to maintain remission conveniently.
• An ulcerative colitis patient continuing infliximab maintenance after IV induction.
• An ankylosing spondylitis patient seeking steady TNF suppression without infusion visits.

Who Is It Best For?

Adults with moderate-to-severe TNF-driven autoimmune disease — inflammatory arthritis or inflammatory bowel disease — who have responded to infliximab and are suitable for subcutaneous maintenance, under specialist care. In rheumatoid arthritis it is used together with methotrexate.

Who Should Avoid It?

• Patients with active tuberculosis or other severe active infections.
• Patients with moderate-to-severe heart failure (NYHA class III/IV).
• Anyone with hypersensitivity to infliximab, other murine proteins, or excipients.
• Patients with untreated latent TB until prophylaxis is started.
• Caution in demyelinating disorders and certain malignancy histories.

How to Use Correctly

1. Treatment starts with loading doses (intravenous or subcutaneous) as your specialist directs, then moves to 120 mg subcutaneously every two weeks.
2. Inject in the thigh or abdomen; rotate sites and avoid tender, bruised, red, or hard skin.
3. Let the pen reach room temperature before injecting for comfort; do not warm it artificially.
4. Do not shake; the solution should be clear to slightly opalescent and colorless to pale yellow.
5. Use each pen once, then dispose of it in a sharps container.
6. In rheumatoid arthritis, continue methotrexate alongside as prescribed.

Best Time to Use

Choose a fixed day for your every-other-week dose and keep to it. Time of day is flexible; consistency of the two-week interval matters most. If a dose is missed, inject as soon as you remember and then continue the regular schedule, unless your specialist advises otherwise.

Common Questions Users Ask

Is Remsima the same as Remicade? It is an approved infliximab biosimilar — the same active substance with demonstrated equivalent quality, safety, and efficacy.

Can I switch from infusions to the pen? Many stable patients transition to subcutaneous maintenance; your specialist plans the switch and timing.

Do I need screening first? Yes — TB and hepatitis screening are standard before any TNF inhibitor.

Expected Results Timeline

Common Mistakes

• Injecting cold straight from the fridge, increasing discomfort.
• Skipping TB or hepatitis screening before starting.
• Stopping when symptoms settle, prompting a flare.
• Receiving live vaccines during treatment without advice.
• Continuing to inject despite signs of a serious infection.

Myths vs Facts

Drug Interactions

• Anakinra and abatacept: combining with infliximab raises infection risk and is not recommended.
• Live vaccines: avoid during treatment; complete them beforehand.
• Methotrexate: given together in rheumatoid arthritis and can reduce anti-drug antibodies.
• Disclose all immunosuppressants and biologics to your specialist before starting.

Contraindications

Hypersensitivity to infliximab, other murine proteins, or any excipient; tuberculosis or other severe active infections including sepsis and opportunistic infections; moderate-to-severe heart failure (NYHA III/IV).

Required Tests

• Tuberculosis screening (IGRA or tuberculin test) plus chest imaging before starting.
• Hepatitis B and C screening before initiation.
• Complete blood count and liver function at baseline and periodically.
• Cardiac and neurological assessment where risk factors exist.
• Up-to-date vaccination review before treatment.

What to Eat With It

Remsima has no specific food interactions. A balanced, anti-inflammatory-leaning diet supports overall control: plenty of vegetables, whole grains, omega-3 sources, and adequate protein. Patients with inflammatory bowel disease should follow the individualized plan set with their gastroenterologist rather than generic advice. Maintain good vitamin D and calcium intake, especially if also on corticosteroids.

Effect on Other Medications

As a biologic antibody, infliximab does not act through liver enzymes the way small-molecule drugs do, so classic pharmacokinetic interactions are limited. The key rules are avoiding combination with certain biologics (anakinra, abatacept), careful vaccine timing, and coordinated use with methotrexate as your specialist directs. Never add or stop another immunosuppressant on your own.

When To See a Doctor

• Signs of infection: persistent fever, cough, night sweats, weight loss (possible TB), or any severe infection.
• Numbness, tingling, vision changes, or weakness — possible neurological effects.
• New or worsening shortness of breath or leg swelling — possible heart failure.
• Injection-site or allergic reactions: swelling, hives, difficulty breathing.
• Unusual bruising, bleeding, or persistent fatigue.

NSL Expert Tip

Conversational FAQ

Can I switch from IV Remicade or Inflectra to Remsima SC?
Many stable patients transition successfully; the decision, loading plan, and monitoring belong to your specialist.

How often do I inject?
The maintenance dose is 120 mg subcutaneously once every two weeks after the loading phase.

Does it need refrigeration?
Yes — keep it at 2–8°C, protect from light, and do not freeze; check the leaflet for any permitted room-temperature window.

Can I travel with it?
Yes, using a cool bag to maintain 2–8°C during transport.

Will it weaken my immunity?
It blocks one inflammatory pathway and does raise infection risk, which is why screening and vigilance matter — but it is targeted, not blanket immunosuppression.

Conclusion

Remsima 120 mg SC brings the proven power of infliximab into a convenient at-home injection, letting suitable patients maintain control of inflammatory arthritis and bowel disease every two weeks. With proper pre-treatment screening, correct technique, vaccine planning, and specialist monitoring, it delivers reliable TNF suppression while sparing infusion visits. It is a prescription-only biologic that must be managed under continuous specialist care.